# US 2003/0229048 A1 · Methods and compositions for inhibition of irritation by disaccharide and metal ions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229048 A1
- Document ID: US20030229048A1
- Status: Published application
- Kind: A1
- Application number: 10/426,941
- Filed: 2003-04-30
- Published: 2003-12-11
- Earliest claimed: 2002-04-30
- Inventors: Dange Veerapaneni; Kazutaka Inoue; Takaaki Yoshinaga; Munehiko Hirano; Shuji Sato
- Web page: https://patentgrep.com/patent/US20030229048A1

## CPC

- A61K 8/60: Sugars; Derivatives thereof
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/7012: Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K31/191; ascorbic acid A61K31/375)
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61Q 17/00: Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61K 2800/70: Biological properties of the composition as a whole
- A61K 2800/75: Anti-irritant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Compositions for reducing an adverse skin reaction caused by a skin-irritating agent or skin sensitizing agent by treatment with a disaccharide and a metal ion, as well as methods for reducing an adverse skin reaction caused by a skin-irritating or skin-sensitizing agent, and methods for treating an inflammatory response to at least one inflammatory agent, by application of a disaccharide and/or metal ion composition.

## Claims

### Claim 1

A composition comprising:
an adverse skin-reactive agent, skin-irritating agent, or skin-sensitizing agent and an adverse skin-reaction preventing, reducing or controlling agent comprising a therapeutically effective amount of a disaccharide and a metal ion.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the skin-sensitizing agent is selected from the group consisting of therapeutic agents, metals, fragrances, cosmetics, textiles, pollen, pesticides, plastics and combinations thereof.

### Claim 3 (depends on 2)

A composition according to claim 2, wherein the therapeutic agent is an agent including an antibiotic, an antiviral, an analgesic and analgesic combination, an anorexic, an antiarthritic, an anti-asthmatic, an anticoagulant, an anticonvulsant, an antidepressant, an anti-diabetic, an antidiarrheal, an antihistamine, an anti-inflammatory agent, an antimigrane agent, an anti-motion sickness preparation, an antinauseant, an antineoplastic, an antiparkinsonism drug, an antipruritic, an antipsychotic, an antipyretic, an antispasmodic, an anticholinergic, a sympathomimetic, a xanthine derivative, a cardiovascular agent, an antiaarrythmic, an antihypertensive, a vasodilator, a central nervous acting agent, a cough and cold preparation, a decongestant, a diagnostic, a hormone, a hypnotic, a muscle relaxant, a parasympatholytic, a parasympathomimetic, a psychostimulant, a sedative, a weight control and appetite suppressive drug, an a tranquilizer.

### Claim 4 (depends on 3)

A composition according to claim 3, wherein the anti-inflammatory agent is an agent including methyl salicylate, acetylsalicylic acid, sodium salicylate, choline salicylate, choline magnesium salicylate, diflunisal, salflex, salicylamide, salsalate, disalcid, trolamine salicylate, trisilate, ketoprofen, prostaglandin, flurbiprofen, diclofenac, indomethacin, piroxicam, and ibuprofen.

### Claim 5 (depends on 1)

A composition according to claim 1, wherein at least one monosaccharide in the disaccharide is selected from a hexose, a pentose, a tetrose and a triose.

### Claim 6 (depends on 1)

A composition according to claim 1, wherein at least one monosaccharide in the disaccharide is selected from erythrose, threose, erythrulose, ribose, arabinose, xylose, lyxose, ribulose, xylulose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, psicose, fructose, sorbose, tagatose, deoxyribose, quinovose, rhamnose, and fucose.

### Claim 7 (depends on 1)

A composition according to claim 1, wherein the disaccharide is a trehalose.

### Claim 8 (depends on 1)

A composition according to claim 1, wherein the metal ion is a divalent metal ion.

### Claim 9 (depends on 8)

A composition according to claim 8, wherein the divalent metal ion is zinc.

### Claim 10 (depends on 1)

A composition according to claim 1, wherein the metal ion is in the form of a metal oxide.

### Claim 11 (depends on 10)

A composition according to claim 10, wherein the metal oxide is zinc oxide.

### Claim 12

A method for treating an adverse skin reaction of the skin in a subject to the presence of at least one of a skin-sensitizing or a skin-irritating agent comprising the steps:
providing an adverse skin reaction preventing, reducing or controlling agent comprising a disaccharide and a metal ion in a formulation; and
topically administering a therapeutically effective amount of the formulation to the subject so as to prevent, reduce or control the adverse skin reaction.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the skin-irritating agent is a compound including water, cleansers, alkalis, acids, oils, organic solvents, oxidizing agents, and combinations thereof.

### Claim 14 (depends on 12)

A method according to claim 12, wherein the skin-sensitizing agent is selected from the group consisting of therapeutic agents, metals, fragrances, cosmetics, textiles, pollen, pesticides, plastics, and combinations thereof.

### Claim 15 (depends on 12)

A method according to claim 12, wherein the adverse skin reaction preventing, reducing or controlling agent is administered transdermally.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the skin-sensitizing agent is a therapeutic agent, the method further comprising administering the adverse skin reaction preventing, reducing or controlling agent and the therapeutic agent from a transdermal patch.

### Claim 17

A method of treating an inflammatory response in a subject to the presence of at least one inflammatory agent comprising the steps:
providing an inflammatory preventing, reducing or controlling agent comprising a disaccharide and a metal ion in a formulation; and
administering an effective dose of the formulation to the subject, so as to prevent, reduce or control the inflammatory response.

### Claim 18 (depends on 17)

A method of treating an inflammatory response in a subject according to claim 17, further comprising administering the effective dose via topical administration including transdermal patch or tape formulation, subcutaneous administration, parentereal administration, intravenous administration, instramuscular administration, and oral administration.

### Claim 19 (depends on 17)

A method of treating an inflammatory response according to claim 17, wherein treatment of the inflammatory response is evidenced by a reduction in the stimulation of cytokines, growth factors, and chemokines relative to the stimulation of cytokines, growth factors and chemokines observed in the absence of administration of an inflammatory preventing, reducing or controlling agent.

### Claim 20 (depends on 19)

A method of treating an inflammatory response according to claim 19, wherein treatment of the inflammatory response is evidenced by a reduction in the stimulation of interleukin-1α and tumor necrosis factor-α chemokines relative to the stimulation of cytokines, growth factors and chemokines observed in the absence of administration of an inflammatory preventing, reducing or controlling agent.

### Claim 21 (depends on 17)

A method of treating an inflammatory response according to claim 17 wherein the inflammatory response is in response to the presence of an agent selected from the group consisting of methyl salicylate, acetylsalicylic acid, sodium salicylate, choline salicylate, choline magnesium salicylate, diflunisal, salflex, salicylamide, salsalate, disalcid, trolamine salicylate, and trisilate.

### Claim 22

A method of treating an adverse reaction of the skin in a subject to the presence of at least one of a skin-sensitizing or a skin-irritating agent comprising the steps:
providing an adverse skin reaction preventing, reducing or controlling agent comprising a disaccharide in a formulation; and
administering an effective amount of the disaccharide formulation to the adverse reactive site of the subject in a suitable carrier so as to prevent, reduce or control the adverse skin reaction.

### Claim 23 (depends on 22)

A method of treating an adverse skin reaction in a subject according to claim 22, further comprising administering the disaccharide formulation via topical administration including transdermal patch or tape formulation, subcutaneous administration, parentereal administration, intravenous administration, instramuscular administration, or oral administration.

### Claim 24

A method of treating an adverse reaction of the skin in a subject to the presence of at least one of a skin-sensitizing or a skin-irritating agent comprising the steps:
providing an adverse skin reaction preventing, reducing or controlling agent comprising a metal ion in a formulation; and
administering an effective amount of the metal ion formulation to the adverse reactive site of the subject in a suitable carrier so as to prevent, reduce or control the adverse skin reaction.

### Claim 25 (depends on 22)

A method of treating an adverse skin reaction in a subject according to claim 22, further comprising administering the metal ion formulation via topical administration including transdermal patch or tape formulation, transdermal administration, subcutaneous administration, parentereal administration, intravenous administration, instramuscular administration, or oral administration.

### Claim 26

A method of treating an inflammatory response in a subject to the presence of at least one inflammatory agent comprising the steps:
providing an inflammatory preventing, reducing or controlling agent comprising a disaccharide in a formulation; and
administering an effective amount of the disaccharide formulation to the subject in a suitable carrier so as to prevent, reduce or control inflammation.

### Claim 27 (depends on 26)

A method of treating an inflammatory response in a subject according to claim 26, further comprising administering the disaccharide formulation via topical administration including transdermal patch or tape formulation, subcutaneous administration, parentereal administration, intravenous administration, instramuscular administration, or oral administration.

### Claim 28

A composition effective in treating an adverse skin reaction comprising:
an adverse skin-reaction preventing, reducing or controlling agent comprising a therapeutically effective amount of a disaccharide and a metal ion.

### Claim 29

A composition effective in treating an inflammatory response comprising:
an inflammatory preventing, reducing or controlling agent comprising a therapeutically effective amount of a disaccharide and a metal ion.
